Free Republic 4th Qtr 2021 Fundraising Target: $88,000 Receipts & Pledges to-date: $75,301
Woo hoo!! And we're now over 85%!! Less than $12.7k to go!! Thank you all very much!! God bless.

Keyword: peptide

Brevity: Headers | « Text »
  • NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19

    03/29/2021 9:19:32 AM PDT · by rxsid · 11 replies ^ | 03.29.2021 | NeuroRx
    NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19 RADNOR, Pa., March 29, 2021 /PRNewswire/ -- NeuroRx, Inc. today reports 60-day results of the Phase 2b/3 trial of intravenously-administered ZYESAMI™ (aviptadil acetate) for the treatment of respiratory failure in critically-ill patients with COVID-19, which is being developed in collaboration with Relief Therapeutics Holding AG (SIX:RLF,OTCQB:RLFTF). Across all patients and sites, ZYESAMI™ met the primary endpoint for successful recovery from respiratory failure at days 28 (P = .014) and 60 (P = .013) and...
  • FDA Lets NeuroRx, Relief Therapeutics Test RLF-100 in COVID-19 Patients (Aviptadil)

    08/06/2020 7:53:28 AM PDT · by rxsid · 28 replies ^ | 08.06.2020 | By Reuters
    FDA Lets NeuroRx, Relief Therapeutics Test RLF-100 in COVID-19 PatientsZURICH — The U.S. Food and Drug Administration has granted NeuroRx Inc Investigational New Drug (IND) permission to test RLF-100 (aviptadil) for inhaled use in patients with moderate and severe COVID-19 to prevent progression to respiratory failure, it and partner Relief Therapeutics Holdings said on Thursday. ... They said aviptadil is shown as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes while also preventing synthesis of cytokines in the lung. ... has been granted FDA fast track designation, FDA emergency use IND...
  • The promising COVID therapy for respiratory failure few have heard of, but will soon - NeuroRx and Relief Therapeutics RLF-100 (Aviptadil)

    08/05/2020 11:21:03 AM PDT · by rxsid · 63 replies ^ | 08.05.2020 | Numerous
    NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted by the FDA to RLF-100 (Aviptadil) for the Treatment of Respiratory Distress in COVID-19 Fast Track Designation of RLF-100 for the treatment of Acute Lung Injury/Acute Respiratory Distress Syndrome associated with COVID-19 underscores the urgent need for new treatment options for these patients. At FDA's request, NeuroRx is submitting an expanded access policy enabling physicians to request RLF-100 for patients who meet this criterion. June 24, 2020 01:30 AM Eastern Daylight Time RADNOR, Pa. & GENEVA--(BUSINESS WIRE)--NeuroRx, Inc. (OTC:RLFTF), in partnership with RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief” today announced that...
  • Newly-Synthesized Peptide Could Disarm SARS-CoV-2 Coronavirus

    04/02/2020 8:17:40 PM PDT · by CutePuppy · 24 replies
    Sci-news ^ | 2020 March 31 | News staff
    Chemists at the Massachusetts Institute of Technology (MIT) have chemically synthesized a new peptide (a short protein fragment) that can bind to part of SARS-CoV-2's spike protein, a key protein responsible for getting the virus into mammalian cells, potentially disarming it. "We have a lead compound that we really want to explore, because it does, in fact, interact with a viral protein in the way that we predicted it to interact, so it has a chance of inhibiting viral entry into a host cell," said senior author Dr. Brad Pentelute, a researcher in the Department of Chemistry at MIT. Coronaviruses,...
  • Biologists' new peptide could fight many cancers

    01/16/2018 2:30:48 PM PST · by Red Badger · 8 replies ^ | January 16, 2018 | by Anne Trafton, & Massachusetts Institute of Technology
    MIT biologists have designed a new peptide that can disrupt a key protein that many types of cancers, including some forms of lymphoma, leukemia, and breast cancer, need to survive. The new peptide targets a protein called Mcl-1, which helps cancer cells avoid the cellular suicide that is usually induced by DNA damage. By blocking Mcl-1, the peptide can force cancer cells to undergo programmed cell death. "Some cancer cells are very dependent on Mcl-1, which is the last line of defense keeping the cell from dying. It's a very attractive target," says Amy Keating, an MIT professor of biology...
  • Immune systems of type 1 diabetics can be ‘retrained’ to stop destroying insulin, scientists show

    08/10/2017 7:54:32 AM PDT · by Red Badger · 12 replies ^ | 9 August 2017 | Sarah Knapton, Science Editor
    The damaged immune systems of diabetics can be ‘retrained’ to stop them destroying insulin, scientists believe, following successful trials of a pioneering new therapy. Researchers at King’s College London and Cardiff University showed that injecting patients with tiny protein fragments prevented immune cells from targeting vital insulin. Type 1 diabetes develops when a patient's immune system mistakenly attacks the insulin producing beta cells in the pancreas. Without treatment the number of beta cells will slowly decrease and the body will no longer be able to maintain normal blood sugar (blood glucose) levels, leading to patients needing daily injections. But a...
  • Is Komodo dragon blood the key to new antibiotics?

    04/12/2017 2:59:17 AM PDT · by csvset · 15 replies
    BBC ^ | 11 April 2017 | Staff
    Is Komodo dragon blood the key to new antibiotics? Komodo dragonScience Photo Library The Komodo dragon is the largest living lizard in the world Komodo dragon blood contains an important compound which scientists think could offer a new treatment for infected wounds. The reptile's saliva harbours many different types of bacteria, which somehow do not affect the dragon. Scientists at George Mason University in the US created a synthetic compound based on a molecule in dragon blood that had antimicrobial activity. They found it promoted the healing of infected wounds in mice. The study - published in npj Biofilms and...
  • (Quick, easy, SARS tests are on the way) Discovery of SARS Antigenic Peptide

    06/16/2003 6:48:06 AM PDT · by Logical Extinction · 25 replies · 187+ views
    Businesswire ^ | 6-15-03
        ROCKVILLE, Md.--(BUSINESS WIRE)--June 16, 2003--Today, Vaxim, Inc., a Rockville Maryland based biopharmaceutical company, announced that it has successfully identified and synthesized a peptide from SARS viral proteins, named V-S26, which is confirmed to bind specifically with serum antibody from SARS recovered patients.     With the focus of vast amount of resources of medical and biological institutes, the immediate need of effective SARS detection, treatment and prevention solutions remain pressing concerns that have not been answered by traditional techniques. Vaxim predicts that the company's novel approach by the quick identification of peptide that interacts with antibody specific to SARS viral proteins, will...